Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.34 |
| ▸ | LIG1 | P18858 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12020373 | 0.81 | MAOA (0.44) | MAOAMAOBKDM1ACCR2PTGS2 | |
| SCHEMBL695920 | 0.78 | HSD17B10 (0.41) | MAOAMAOBKDM1AHSD17B10DRD2 | |
| SCHEMBL6498103 | 0.75 | HDAC4 (0.44) | HSD17B10DRD2HSD11B1HDAC4 | |
| SCHEMBL620974 | 0.75 | HSD11B1 (0.41) | CCR2HSD17B10DRD2HSD11B1LIG1 | |
| SCHEMBL28800669 | 0.73 | MAOA (0.42) | MAOAMAOBKDM1ACCR2HSD17B10 | |
| SCHEMBL10879701 | 0.73 | SLC6A4 (0.47) | HSD11B1HDAC4 | |
| SCHEMBL20187414 | 0.71 | MAOA (0.53) | MAOAMAOBKDM1ACCR2PTGS2 | |
| SCHEMBL17872734 | 0.71 | KDM1A (0.48) | MAOAMAOBKDM1ACCR2PTGS2 | |
| SCHEMBL17872736 | 0.71 | KDM1A (0.48) | MAOAMAOBKDM1ACCR2PTGS2 | |
| SCHEMBL17872738 | 0.71 | KDM1A (0.48) | MAOAMAOBKDM1ACCR2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1353896-A2 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF HYDROXYLATED CYCLOBUTYLALKYLAMINES | Sepracor Inc. (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20020115727-A1 | Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines | SEPRACOR INC. | 2002-08-22 | — | — | US | disclosed |
| WO-2002046138-A2 | SYNTHESIS, METHODS OF USING, AND COMPOSITIONS OF HYDROXYLATED CYCLOBUTYLALKYLAMINES | SEPRACOR INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115727-A1 | Synthesis, methods of using, and compositions of hydroxylated cyclobutylalkylamines | HTR5A, TPH1, HTR1B | MAOA 19/4885MAOB 22/4885KDM1A 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.